ArticleCureus2026
Kidney Biopsy in Cancer Patients With Acute Kidney Disease: Histological Findings and Kidney Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims The incidence and prevalence of acute kidney disease (AKD), including acute kidney injury (AKI) and proteinuria, are increased in cancer patients. This study aimed to investigate the variety of renal histopathological lesions in cancer patients and their associations with systemic anticancer therapies (SACT) before and after 2017, the year when new SACTs like immune checkpoint inhibitors and target therapies were generally introduced, as well as the role of kidney biopsy (KB) in guiding treatment decisions. Material and methods This retrospective cohort study included adult cancer patients who underwent kidney biopsy for AKD at a single center over a 14-year period. Clinical, laboratory, and renal histopathological data were collected, and therapeutic options were evaluated. The study cohort was stratified into three groups - (i) SACT-related AKD, (ii) cancer-related AKD, and (iii) non-SACT/non-cancer-related AKD - based on clinical judgment by the treating nephrologist, allowing detailed characterization of AKD patterns. Results Fifty-five patients (61.8% men; mean age 64.7±9.9 years) were included. At diagnosis, median serum creatinine was 2.2 mg/dl (interquartile range (IQR) 1.6-4) and proteinuria 1.3 g/24h (IQR 0.25-4). Most patients (63.6%) were receiving SACT. Glomerulopathies were the most frequent lesions (43.6%), with focal segmental glomerulosclerosis (FSGS) predominating (29%). Acute interstitial nephritis (AIN), acute tubular injury (ATI), and mixed AIN/ATI were identified in 21.8%, 12.7%, and 9.1% of cases, respectively, while renal tumor infiltration occurred in 7.3%. AKD was attributed to SACT in 41.8%, most commonly immunotherapy (52.2%), and AIN was the prevailing lesion (82.6%). A significant shift in histopathological patterns was observed after 2017 (p=0.006), with higher frequencies of glomerulonephritis (51.3% vs. 25%) and acute tubulointerstitial nephritis (25.6% vs. 12.5%). Among patients receiving targeted treatment based on KB findings, including corticosteroid therapy, all experienced favorable renal outcomes. Conclusions This study highlights the expanding spectrum of kidney injury in cancer patients, the influence of modern SACT on renal pathology, and the critical role of kidney biopsy in guiding individualized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.